- 询价
- 上海
- 吉满生物提供的过表达慢病毒产品适合于人源、小鼠、大鼠等物种的基因的表达。
- 2025年12月24日
24h回复
售后服务
技术支持
文献支持
13 年皇冠会员
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 用户评价
- 文献和实验
- 技术资料
- 服务名称：
cDNA lentiviral construct and packaging services
- 提供商：
吉满生物
- 规格：
询价
吉满慢病毒包装平台
吉满慢病毒包装服务流程
产品简介
将慢病毒载体的过表达质粒，与慢病毒包装辅助质粒和包膜质粒共转染293T细胞，收集上清进行浓缩纯化，获取高滴度的慢病毒，可用于直接感染目的细胞，获得过表达目的基因的细胞系，以用于基因功能研究。
案例展示
1、使用吉满生物提供的ALKBH5过表达慢病毒感染BxPC-3细胞，经RT-qPCR和western Blot验证：感染ALKBH5慢病毒后，ALKBH5的表达量显著上调；(Mol Cancer. 2020 May 19;19(1):91.)
2、使用吉满生物提供STAT3过表达慢病毒感染MLE12细胞，并进行OGD/R诱导，发现STAT3过表达后，SLC7A11和pSTAT3的表达量显著增加；(Oxid Med Cell Longev. 2020 Sep 18;2020:5146982. )
可供选择的载体
| 载体编号 | 元件顺序 | 用途 | 基因导入 | 真核抗性 | 荧光标记 |
| pGMLV-PA1 | CMV-MCS-IRES-GFP | 过表达 | 慢病毒载体 | / | GFP |
| pGMLV-PA2 | CMV-MCS-IRES-RFP | 过表达 | 慢病毒载体 | / | RFP |
| pGMLV-PA3 | CMV-MCS-2A-GFP | 过表达 | 慢病毒载体 | / | GFP |
| pGMLV-PA4 | EF 1-MCS-IRES-puromycin | 过表达 | 慢病毒载体 | Puromycin | / |
| pGMLV-PA5 | EF 1-MCS-IRES-GFP | 过表达 | 慢病毒载体 | / | GFP |
| pGMLV-PB1 | CMV-MCS-GFP-PGK-puromycin | 过表达 | 慢病毒载体 | Puromycin | GFP |
| pGMLV-PB2 | CMV-GFP-MCS-PGK-puromycin | 过表达 | 慢病毒载体 | Puromycin | GFP |
| pGMLV-PB3 | CMV-MCS-RFP-PGK-puromycin | 过表达 | 慢病毒载体 | Puromycin | RFP |
| pGMLV-PB4 | CMV-RFP-MCS-PGK-puromycin | 过表达 | 慢病毒载体 | Puromycin | RFP |
| pGMLV-PB5 | SV40-Neomycin-CMV-MCS-GFP | 过表达 | 慢病毒载体 | Neomycin | GFP |
| pGMLV-PB6 | SV40-Neomycin-CMV-MCS-RFP | 过表达 | 慢病毒载体 | Neomycin | RFP |
| pGMLV-PC1 | MCS-Metluciferase | 报告基因 | 慢病毒载体 | / | / |
| pGMLV-PD1 | TRE2-MCS-IRES-EGFP | 诱导表达 | 慢病毒载体 | / | EGFP |
| pGMLV-PD2 | Ptight-MCS-PGK-puromycin | 诱导表达 | 慢病毒载体 | Puromycin | / |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
用户评价
暂无用户评价
文献和实验该产品被引用文献
IF-41.443 Jin S F,Li M Y,Chang H Y,et al. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma[J]. Molecular Cancer, 2022, 21(1):1-19.
IF=41.443 Zhang L X,Gao J,Long X,et al. The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis[J]. Molecular Cancer, 2022, 21(1):1-20.
IF=41.443 Chen S W,Zhu S Q, Pei X,et al. Cancer cell-derived exosomal circUSP7 induces CD8 + T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC[J]. Molecular cancer, 2021;20(1):144.
IF=23.177 Xia A X,Yuan W W,Wang Q,et al. The cancer-testis IncRNA Inc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription[J]. Nature cancer. 2022(3-2).
IF=17.521 Han D W,Wang L J,Long L,et al. The E3 Ligase TRIM4 Facilitates SET Ubiquitin-Mediated Degradation to Enhance ER-α Action in Breast Cancer[J]. Advanced Science,2022;9(25).
IF=17.521 Wang L L,Shen Q,Liao H Z,et al. Multi Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation[J]. Advanced Science, 2021;8(11).
IF=17.521 Liu Q D, Sheng Z H, Cheng C,et al. Anesthetic Propofol Promotes Tumor Metastasis in Lungs via GABAA R-Dependent TRIM21 Modulation of Src Expression.[J]. Advanced Science,.2021;8(18)
IF=16.873 Lin S,Yin S,Shi J F,et al. Orchestration of energy metabolism and osteogenesis by Mg2+ facilitates low-dose BMP-2-driven regeneration[J]. Bioact Mater. 2022;18:116-127.
IF=15.304 Wang F,Qian J,Yang M Y,et al. MiR-6924-5p-rich exosomes derived from genetically modified Scleraxis-overexpressing PDGFRα(+) BMMSCs as novel nanotherapeutics for treating osteolysis during tendon-bone healing and improving healing strength[J]. Biomaterials, 2021, 279:121242.
IF=15.282 Ju H Y, Hu Z R, Wei L D,et al. A novel intronic circular RNA, circGNG7, inhibits head and neck squamous cell carcinoma progression by blocking the phosphorylation of heat shock protein 27 at Ser78 and Ser82[J]. Cancer Communications, 2021;41(11):1152-1172.
IF=12.658 Zhu M X,Zhang P F,Yu S,et al. Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer[J]. Journal of Experimental & Clinical Cancer Research, 2022, 41(1):1-20
IF=12.658 Zhu J J,Cai T T,Zhou J Q,et al. CD151 drives cancer progression depending on integrin α3β1 through EGFR signaling in non-small cell lung cancer[J]. Journal of experimental & clinical cancer research , 2021;40(1):192.
IF=41.443 Zhang L X,Gao J,Long X,et al. The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis[J]. Molecular Cancer, 2022, 21(1):1-20.
IF=41.443 Chen S W,Zhu S Q, Pei X,et al. Cancer cell-derived exosomal circUSP7 induces CD8 + T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC[J]. Molecular cancer, 2021;20(1):144.
IF=23.177 Xia A X,Yuan W W,Wang Q,et al. The cancer-testis IncRNA Inc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription[J]. Nature cancer. 2022(3-2).
IF=17.521 Han D W,Wang L J,Long L,et al. The E3 Ligase TRIM4 Facilitates SET Ubiquitin-Mediated Degradation to Enhance ER-α Action in Breast Cancer[J]. Advanced Science,2022;9(25).
IF=17.521 Wang L L,Shen Q,Liao H Z,et al. Multi Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation[J]. Advanced Science, 2021;8(11).
IF=17.521 Liu Q D, Sheng Z H, Cheng C,et al. Anesthetic Propofol Promotes Tumor Metastasis in Lungs via GABAA R-Dependent TRIM21 Modulation of Src Expression.[J]. Advanced Science,.2021;8(18)
IF=16.873 Lin S,Yin S,Shi J F,et al. Orchestration of energy metabolism and osteogenesis by Mg2+ facilitates low-dose BMP-2-driven regeneration[J]. Bioact Mater. 2022;18:116-127.
IF=15.304 Wang F,Qian J,Yang M Y,et al. MiR-6924-5p-rich exosomes derived from genetically modified Scleraxis-overexpressing PDGFRα(+) BMMSCs as novel nanotherapeutics for treating osteolysis during tendon-bone healing and improving healing strength[J]. Biomaterials, 2021, 279:121242.
IF=15.282 Ju H Y, Hu Z R, Wei L D,et al. A novel intronic circular RNA, circGNG7, inhibits head and neck squamous cell carcinoma progression by blocking the phosphorylation of heat shock protein 27 at Ser78 and Ser82[J]. Cancer Communications, 2021;41(11):1152-1172.
IF=12.658 Zhu M X,Zhang P F,Yu S,et al. Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer[J]. Journal of Experimental & Clinical Cancer Research, 2022, 41(1):1-20
IF=12.658 Zhu J J,Cai T T,Zhou J Q,et al. CD151 drives cancer progression depending on integrin α3β1 through EGFR signaling in non-small cell lung cancer[J]. Journal of experimental & clinical cancer research , 2021;40(1):192.
相关实验
特异性更高。您可以根据实验设计需要进行选择。 2、慢病毒包装载体：Cas9 慢病毒表达载体采用 3 质粒慢病毒系统。您可使用我公司的 pH1、pH2；addgene 载体 psPAX2、pMD2.G 或者 pCMV-dR8.2 dvpr、pCMV-VSVG 均可包装成功。 3、无内毒素质粒提取试剂盒。使用质量可靠的质粒提取试剂盒可以提供更高的转染效率和病毒包装效率。我们采用 Qiagen 的 Plasmid Plus 系列产品可以取得满意的包装效果。 4、转染
作为细胞生物学专业的博士生，在基因功能研究上已经有五年的经验了，今天我给大家讲讲其中经常用到并且非常重要的一种技术--慢病毒包装的过表达体系。下面我就从引物设计，慢病毒表达质粒构建等方面详细讲述。下面以 plex-MCS 载体为例。1. 选择酶切位点，为了避免移码突变，上游的酶切位点选择起始密码子 ATG 前面的 spel，下游选择 xho1。2. 构建方法的选择。连接法对于连接法，首先设计引物将目的基因 PCR 出来，即酶切位点加基因引物，此时应注意，为了防止酶切将基因破坏，通常习惯在两端
分为五步，即gRNA文库选择、gRNA文库扩增、gRNA文库慢病毒包装、gRNA文库筛选、PCR扩增和NGS测序 1、gRNA文库选择 首先客户选择所需gRNA文库。如果客户根据具体需要提出文库定制（小于300个基因），我们将根据客户提供的基因群信息进行单个基因的gRNA设计，保证每个基因设计3个不同的gRNA，最大程度确保基因功能的突变。我们采用的载体是单/双慢病毒载体，单慢病毒载体是一个载体上同时携带单个gRNA和cas9基因，双慢病毒载体是一个载体上只有单个gRNA，cas9蛋白则由单独
研选
过表达慢病毒构建与包装定制
询价
